Peptide Database

A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.

A fusion protein combining the ligand-binding domain of the activin type IIB receptor (ACVR2B) with the Fc region of human IgG1. Acts as a decoy receptor for multiple TGF-beta superfamily members including myostatin, activin A, GDF-11, and BMP9, simultaneously blocking all of them to produce dramatic increases in muscle mass.

A highly experimental proapoptotic peptide that selectively destroys the blood supply to white adipose tissue. Dramatic fat loss in animal models but significant renal toxicity concerns.

A tripeptide (Ala-His-Lys) copper complex that acts as a hair follicle stimulant, distinct from GHK-Cu. AHK-Cu specifically activates hair follicle stem cells and has been shown in in vitro studies to increase hair follicle size and activity by 153%, making it more hair-growth focused than GHK-Cu while sharing similar anti-aging and wound healing properties.

A naturally occurring nucleoside and potent AMPK (AMP-activated protein kinase) activator. Mimics the cellular effects of exercise by activating energy-sensing pathways. Studied for metabolic disease, exercise performance, fat oxidation, and cancer treatment.

A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.

A synthetic 11-amino acid peptide that mimics the tissue-protective actions of erythropoietin without its erythropoietic effects. Highly effective for neuropathic pain and nerve repair.

A selective mitochondrial uncoupler that increases energy expenditure by diverting the proton gradient from ATP synthesis to heat production. In mouse models, BAM15 reversed diet-induced obesity and insulin resistance without increasing body temperature, heart rate, or affecting the plasma membrane — overcoming the critical safety limitations of earlier uncouplers like DNP.

A 15-amino acid peptide fragment derived from a protective protein found in gastric juice. Remarkably effective at accelerating healing of tendons, ligaments, muscles, and gut tissue.

A tetrapeptide (Ala-Glu-Asp-Leu) from the Khavinson bioregulator series specifically targeting bronchial and lung tissue. Studied for COPD, chronic bronchitis, and smoking-related lung damage. Normalizes bronchial epithelium proliferation and reduces respiratory inflammation.

A long-acting amylin analog being co-developed with semaglutide (as CagriSema) for obesity. Amylin signals satiety to the brain independently of GLP-1, making the combination synergistic for weight loss.

A tetrapeptide cardiac bioregulator from the Khavinson series targeting myocardial tissue. Normalizes myocardial cell function, reduces cardiac oxidative stress, and provides cardioprotection against ischemia and aging-related cardiac decline. Studied for heart failure, cardiomyopathy, and post-infarction recovery.

A cartilage and bone-targeting peptide bioregulator from the Khavinson series. Studied for arthritis, osteochondrosis, fracture recovery, and joint aging. Stimulates chondrocyte proliferation and collagen synthesis in cartilage tissue, supporting structural repair and maintenance of joint integrity.

A complex mixture of low-molecular-weight neuropeptides derived from porcine brain proteins. The only peptide-based nootropic with robust clinical evidence for Alzheimer disease and brain injury.

A peptide bioregulator targeting bronchial mucosa from the Khavinson series. Distinct from Bronchogen (which targets bronchial parenchyma), Chonluten specifically targets the mucous membrane lining of the bronchi. Studied for COPD, chronic mucus hypersecretion, and respiratory tract aging.

A synthetic analog of growth hormone-releasing hormone (GHRH) that extends the half-life of endogenous GHRH. One of the most popular peptides for muscle growth and fat loss when stacked with a GHRP like Ipamorelin.

A synthetic 29-amino acid GHRH analog with 4 amino acid substitutions that improve stability and receptor affinity compared to Sermorelin. Unlike CJC-1295 DAC, it has no Drug Affinity Complex, giving it a short 30-minute half-life that mimics the body's natural pulsatile GHRH secretion when co-administered with a GHRP.

A peptide bioregulator targeting the cerebral cortex and CNS from the Khavinson series. Normalizes cortical neuron function, reduces age-related neurodegeneration, and improves cognitive function. Particularly studied for age-associated cognitive decline, vascular dementia, and post-stroke recovery.

An angiotensin IV-derived peptide that is reportedly millions of times more potent than BDNF at forming functional synaptic connections. Promotes dendritic spine growth via the HGF/c-Met signaling pathway. Researched for Alzheimer's disease, cognitive enhancement, and neuroplasticity.

A neuropeptide that promotes slow-wave (delta wave) sleep and modulates stress hormones. Used for sleep optimization, stress reduction, and recovery enhancement.

The active trans-isomer of clomiphene citrate that acts as a selective estrogen receptor modulator (SERM). Blocks pituitary estrogen receptors to increase LH/FSH production and downstream testosterone synthesis. Studied for male hypogonadism as an alternative to TRT that preserves fertility and natural testosterone production.

A natural pineal gland peptide bioregulator complex. Distinct from Epithalon (synthetic tetrapeptide) and Pinealon (synthetic tripeptide), Endoluten contains natural pineal peptide fractions that regulate melatonin production, circadian rhythms, and age-related neuroendocrine decline.

A synthetic tetrapeptide that activates telomerase, the enzyme responsible for lengthening telomeres. One of the only compounds with robust evidence for telomere extension in humans.

A truncated 315-amino acid isoform of follistatin that lacks the heparin-binding domain, giving it a shorter half-life and more localized action compared to Follistatin-344. Still potently inhibits myostatin and activin for muscle growth but with a different distribution profile.

A naturally occurring protein that inhibits myostatin and activin, effectively removing the biological ceiling on muscle growth.

A D-retro-inverso peptide that selectively induces apoptosis (programmed cell death) in senescent "zombie" cells. Based on a landmark 2017 Nature Medicine paper by van Deursen et al., it is one of the most targeted senolytic compounds under research.

A naturally occurring copper-binding tripeptide that declines with age. Promotes skin rejuvenation, wound healing, hair growth, and anti-inflammatory effects. One of the most studied anti-aging peptides.

A second-generation GHRP with high GH-releasing potency and a cleaner side effect profile than GHRP-6. Less appetite stimulation makes it preferable for body recomposition.

One of the first synthetic GHRPs developed, GHRP-6 is a potent GH secretagogue that also significantly stimulates appetite through ghrelin receptor activation.

An adrenal gland-targeting peptide bioregulator. Normalizes adrenal cortex cell function and cortisol synthesis, reduces adrenal fatigue, and supports HPA axis recovery. Studied for HPA dysregulation, adrenal insufficiency, and stress-related aging.

A 33-amino acid intestinal peptide secreted from L-cells of the gut that promotes intestinal mucosal growth, improves gut barrier function, and reduces inflammation. The FDA-approved analog Teduglutide (Gattex) is used for short bowel syndrome. GLP-2 research focuses on gut permeability, IBS/IBD, Crohn's disease, and gut-brain axis effects.

A synthetic form of endogenous GnRH that stimulates the pituitary to release LH and FSH. Widely used in TRT protocols to maintain testicular size and function.

A synthetic hexapeptide GHRP with the highest GH-releasing potency among the GHRP family. Notable for both its muscle-building effects and documented cardiovascular benefits.

The original C-terminal fragment of human growth hormone spanning amino acids 176-191. Contains the fat-burning region of HGH without the growth-promoting (IGF-1-stimulating) region. Slightly different structure from AOD-9604 but essentially the same compound; AOD-9604 is a modified version with a disulfide bridge.

A urinary-derived combination of LH and FSH used clinically for fertility treatment and in TRT protocols for testicular stimulation and spermatogenesis support.

A 21-amino acid mitochondria-derived peptide encoded in the 12S rRNA gene of the mitochondrial genome. The first discovered mitochondrial-derived peptide (MDP). Humanin protects neurons from Alzheimer-related toxicity, reduces cell death in multiple disease models, and has demonstrated significant anti-aging and longevity effects in animal studies.

A truncated analog of IGF-1 missing the first 3 amino acids from the N-terminus. This modification dramatically reduces its affinity for IGF-binding proteins (IGFBPs), making it approximately 10x more potent than native IGF-1 at the receptor level, with a much shorter half-life ideal for local/acute muscle actions.

A long-acting analog of IGF-1 with a modified arginine substitution that extends its half-life. Directly stimulates muscle protein synthesis independent of GH.

A selective growth hormone secretagogue and ghrelin mimetic that stimulates GH release without significantly elevating cortisol or prolactin. One of the cleanest and most widely used peptides for body recomposition.

A 10-amino acid neuropeptide that acts as the master regulator of the reproductive hormonal axis by stimulating GnRH release. Supports testosterone, libido, fertility, and sexual health.

A naturally occurring tripeptide (Lys-Pro-Val) derived from the C-terminus of alpha-MSH. Anti-inflammatory, antimicrobial, and gut-protective without causing skin pigmentation. Highly studied for IBD, Crohn's disease, skin conditions, and wound healing.

The body's master antioxidant and a tripeptide (Glu-Cys-Gly) found in virtually every cell. Injectable and IV glutathione dramatically raises systemic levels for anti-aging, skin brightening, neuroprotection, liver detoxification, and chronic disease management. Oral bioavailability is poor; injectable forms bypass absorption limitations.

An 8-amino acid synthetic peptide designed to regulate tight junctions between intestinal epithelial cells. Directly targets intestinal permeability (leaky gut) and is the only compound in clinical trials specifically for tight junction regulation in celiac disease.

An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes and weight management. Produces 5-8% average weight loss with established cardiovascular safety data.

A synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson bioregulator series that de-heterochromatinizes age-condensed chromatin in lymphocytes, restoring youthful gene expression patterns. Hepatoprotective and immunomodulatory. One of the most mechanistically unique anti-aging peptides — it directly reactivates genes silenced by chromatin condensation with age.

The only human cathelicidin antimicrobial peptide, naturally produced by immune cells as a first-line defense. Has broad-spectrum antimicrobial, wound healing, and immunomodulatory properties.

An orally active ghrelin receptor agonist FDA-approved as a diagnostic test for adult growth hormone deficiency. Provides a convenient oral GH stimulation test.

A GLP-1 and glucagon receptor co-agonist developed by Innovent Biologics. In Phase 3 clinical trials in China with strong efficacy data. Shows comparable weight loss to tirzepatide while also reducing liver fat. Also studied for type 2 diabetes management.

A synthetic analog of alpha-MSH that stimulates melanin production for skin tanning. The more selective of the two Melanotan variants, with FDA-orphan drug status for erythropoietic protoporphyria.

A broader-acting melanocortin peptide that stimulates both melanin production and the sexual arousal pathway. Produces potent tanning effects and is also used for erectile dysfunction.

The first synthetic drug ever made (1876), now being rediscovered as a potent mitochondrial electron carrier and cognitive enhancer. Acts as an alternative electron acceptor in the mitochondrial electron transport chain, enhancing ATP production and reducing oxidative stress.

A splice variant of IGF-1 released in muscle fibers in response to mechanical damage. Activates muscle satellite cells to initiate repair and hypertrophy.

A non-peptide, orally active growth hormone secretagogue that mimics ghrelin, significantly elevating GH and IGF-1 levels. Unique in being orally bioavailable.

A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.

A coenzyme found in all living cells, essential for cellular energy production, DNA repair, and sirtuin activation. NAD+ levels decline with age by up to 50%, contributing to metabolic dysfunction and aging. Injectable NAD+ therapy is studied for anti-aging, addiction treatment, and neurological disease.

A direct precursor to NAD+ that is more bioavailable than NAD+ itself. NMN is converted to NAD+ via the NMN/NR pathway in cells. Extensively studied in David Sinclair's lab as a longevity compound.

A synthetic dipeptide nootropic approximately 1000x more potent than piracetam. Stimulates BDNF and NGF expression with significant neuroprotective and cognitive-enhancing effects.

The first truly oral (tablet) GLP-1 receptor agonist that is a small molecule — not a peptide requiring oral protection like semaglutide (Rybelsus). Phase 3 trials showed 14.7% weight loss, close to injectable semaglutide. No needle required — once-daily pill with no food restrictions.

A peptide bioregulator targeting ovarian tissue from the Khavinson series. Studied for female reproductive aging, premature ovarian insufficiency, menopause symptom management, and ovarian reserve support. Normalizes follicular cell function and ovarian hormone synthesis.

A 9-amino acid neuropeptide produced in the hypothalamus that plays a central role in social bonding, trust, reproduction, and wound healing. Studied for autism spectrum disorder, anxiety, social behavior, and relationship enhancement.

A synthetic peptide derived from ciliary neurotrophic factor (CNTF) that increases BDNF production, enhances neuroplasticity, and improves cognitive function. Shows promise for Alzheimer's disease, depression, and age-related cognitive decline.

A synthetic pancreatic peptide bioregulator targeting pancreatic islet cell function. Normalizes insulin secretion, improves beta-cell function, and reduces pancreatic oxidative stress. Studied for type 2 diabetes prevention, metabolic syndrome, and pancreatic aging.

A synthetic heptapeptide derived from the prosegment of sortilin that acts as a selective TREK-1 potassium channel antagonist. Produces rapid antidepressant effects within 4 days — far faster than SSRIs — and demonstrates neuroprotection in stroke and ischemia models.

The PEGylated (polyethylene glycol-conjugated) form of Mechano Growth Factor (MGF), extending its extremely short native half-life from minutes to 24-72 hours. This systemic form activates muscle satellite cells throughout the body rather than only at the injection site, making it suitable for systemic muscle recovery and anti-aging applications.

A synthetic tripeptide (Glu-Asp-Arg) from the Khavinson peptide bioregulator series targeting the brain and pineal gland. Reduces neuronal apoptosis, improves cognitive function in aging models, and normalizes circadian rhythm disruption. Distinct from Epithalon despite also targeting the pineal gland.

A chimeric anticancer peptide fusing a p53 MDM-2 binding domain with a penetratin membrane-translocation region. Selectively forms pores in cancer cell membranes that overexpress HDM-2 (human MDM-2 oncoprotein), causing rapid membranolysis and cancer cell death while sparing normal cells.

An FDA-approved melanocortin agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally via the CNS to increase sexual desire and arousal in both men and women.

An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.

A synthetic heptapeptide derived from tuftsin that exhibits anxiolytic, nootropic, and immunomodulatory effects. Considered a milder anxiolytic counterpart to Semax with a strong safety profile.

An enhanced form of Selank with N-acetyl and C-terminal amide modifications that increase potency and stability. Approximately 2x more potent than standard Selank with longer duration of action.

An FDA-approved GLP-1 receptor agonist that produces significant weight loss (average 14.9% body weight in clinical trials). One of the most clinically validated weight loss peptides available.

A synthetic heptapeptide derived from ACTH 4-7 that significantly boosts BDNF levels. Widely used in Russia for cognitive enhancement, stroke recovery, and neurological conditions.

A modified form of Semax with both N-terminal acetylation and C-terminal amidation, making it 2-3x more potent than standard Semax and more resistant to enzymatic degradation. The preferred form for cognitive enhancement due to its improved bioavailability and stability.

A 29-amino acid synthetic analog of endogenous GHRH that stimulates natural GH production. Clinically used for GH deficiency and widely used in anti-aging medicine as a safer alternative to exogenous HGH.

A pan-agonist of all three estrogen-related receptors (ERRα, ERRβ, ERRγ) that activates the same genetic programs triggered by endurance exercise. Mice given SLU-PP-332 showed 70% greater endurance capacity and significant fat loss without exercise.

A synthetic octapeptide designed to mimic the N-terminal end of the SNAP-25 protein, competing with its binding site in the SNARE complex. Inhibits neuromuscular vesicle fusion at the dermal-epidermal junction, reducing expression-line depth and preventing dynamic wrinkle formation. Often called the "topical alternative to Botox."

A mitochondria-targeted tetrapeptide that localizes to the inner mitochondrial membrane, reduces oxidative stress, and restores ATP production. In Phase 2/3 clinical trials for mitochondrial myopathy, heart failure, and age-related diseases.

A dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2b trials showed superior weight loss to semaglutide at 6 months. Also being studied for NASH/MASH (metabolic steatohepatitis), a liver disease with limited treatment options.

A liver-targeting tetrapeptide bioregulator. Normalizes hepatocyte function, reduces liver fibrosis, improves bile acid metabolism, and protects against hepatotoxicity. Studied for NAFLD, alcohol-related liver damage, hepatitis recovery, and liver aging.

A synthetic version of Thymosin Beta-4, a naturally occurring protein present in nearly all human cells. Promotes cellular healing, anti-inflammation, and tissue regeneration throughout the entire body.

An FDA-approved synthetic GHRH analog originally developed to treat HIV-associated lipodystrophy. Highly effective at reducing visceral adipose tissue.

A serotonin-noradrenaline-dopamine reuptake inhibitor (SNDRI) originally developed for Parkinson and Alzheimer disease. In Phase 2 obesity trials, produced 12.8% weight loss over 6 months — more than twice that of approved weight loss drugs at the time.

A tetrapeptide (Lys-Glu-Asp-Glu estimated) testes-targeting bioregulator from the Khavinson series. Normalizes Leydig cell function, testosterone synthesis, and testicular morphology. Used in male reproductive aging, hypogonadism research, and testosterone support protocols.

A polypeptide complex extracted from calf thymus gland that broadly modulates immune function. Distinct from Thymosin Alpha-1 (a single purified peptide), Thymalin is a complex mixture of thymic peptides. Russian clinical trials show 2-2.4x reduction in acute respiratory infections and significant mortality reduction in elderly patients.

A 28-amino acid peptide naturally produced by the thymus gland that modulates both innate and adaptive immunity. Approved under the name Zadaxin in some countries for hepatitis B, C, and as a vaccine adjuvant.

A synthetic 4-amino acid fragment (Ac-SDKP) derived from the N-terminus of Thymosin Beta-4. This specific fragment is responsible for many of TB-500's anti-inflammatory, stem cell mobilization, and cardiac healing properties, in a more targeted and stable form.

The only true thymic hormone (not a thymosin). A zinc-dependent nonapeptide naturally produced by thymic epithelial cells that directly matures T-lymphocytes. Levels decline ~90% between ages 20-60, making it a key driver of immunosenescence. Requires zinc coordination to be biologically active. Distinct from Thymalin (polypeptide extract) and Thymosin Alpha-1.

A thyroid-targeting tetrapeptide bioregulator from the Khavinson series. Normalizes thyroid cell function, thyroid hormone synthesis, and thyroid morphology. Studied for hypothyroidism, autoimmune thyroiditis, and thyroid aging. One of the most widely used Khavinson organ bioregulators given the high prevalence of thyroid dysfunction.

A dual GLP-1 and GIP receptor agonist representing the next generation of metabolic peptides. Achieves greater weight loss than semaglutide with average reductions of 20-22.5% body weight.

A peptide bioregulator targeting blood vessel walls from the Khavinson series. Normalizes vascular endothelial cell function, reduces oxidative damage to vessel walls, and improves microcirculation. Distinct from Vesugen (which is the synthetic tripeptide form) in being the natural extract-based vascular bioregulator complex.

A synthetic tripeptide from the Khavinson bioregulator series designed to support vascular health and blood vessel integrity.

A synthetic dipeptide from the Khavinson bioregulator series. Primarily acts as a thymus and immune regulator with demonstrated anti-aging properties.